Trial Profile
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs TG 4010 (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Erlotinib; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms TIME
- Sponsors Transgene
- 06 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database
- 28 Jul 2020 This trial is completed in UK (Global End Date: 05 Jul 2016), according to European Clinical Trials Database record.
- 30 Oct 2017 According to a Transgene media release, data from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) Meeting 2017.